The company reported strong growth for Kedrab and Cytogam products, with an estimated market share of 40-50%. InnovAte trial enrollment is at 50%, with ongoing discussions with the FDA.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay
✖
Stocks News
Ultimate Stock News Source